Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Topotecan (as hydrochloride)
Accord Healthcare Limited
L01XX; L01XX17
Topotecan (as hydrochloride)
1 milligram(s)/millilitre
Concentrate for solution for infusion
Product subject to prescription which may not be renewed (A)
Other antineoplastic agents; topotecan
Not marketed
2012-05-04
PACKAGE LEAFLET: INFORMATION FOR THE USER TOPOTECAN 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION TOPOTECAN Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor,pharmacist or nurse. - If you get any side effects, talk to your doctor,pharmacist or nurse. This includes any possible side effects not listed in this leaflet see section 4. WHAT IS IN THIS LEAFLET: 1. What Topotecan 1 mg/ml concentrate for solution for infusion is and what it is used for 2. What you need to know before you are given Topotecan 1 mg/ml concentrate for solution for infusion 3. How to use Topotecan 1 mg/ml concentrate for solution for infusion 4. Possible side effects 5. How to store Topotecan 1 mg/ml concentrate for solution for infusion 6. Contents of the pack and other information 1. WHAT TOPOTECAN 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION IS AND WHAT IT IS USED FOR Topotecan 1 mg/ml concentrate for solution for infusion helps to destroy tumours. A doctor or a nurse will give you the medicine as an infusion into a vein (a drip) in hospital. Topotecan 1 mg/ml concentrate for solution for infusion is used to treat: - ovarian cancer or small cell lung cancer that has come back after chemotherapy - advanced cervical cancer if surgery or radiotherapy treatment is not possible. When treating cervical cancer, Topotecan 1 mg/ml concentrate for solution for infusion is combined with another medicine called cisplatin. Your doctor will decide with you whether Topotecan 1 mg/ml concentrate for solution for infusion therapy is better than further treatment with your initial chemotherapy. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN TOPOTECAN 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION YOU SHOULD NOT RECEIVE TOPOTECAN 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION: - if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section 6). - i Διαβάστε το πλήρες έγγραφο
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Topotecan Accord 1mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride). Each 1 ml vial of concentrate contains 1 mg topotecan (as hydrochloride) Each 4 ml vial of concentrate contains 4 mg topotecan (as hydrochloride) For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. A clear yellow colour solution free from visible foreign particles. pH in the range of 1.5 to 2.5 and Osmolarity in the range of approximately 100 to 40 mOsm/Litre 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topotecan monotherapy is indicated for the treatment of: Patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy. Topotecan should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section 6.6). POSOLOGY When topotecan is used in combination with cisplatin, the full prescribing information for cisplatin should be consulted. Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of 1.5 x 10 9 /l, a platelet count of 100 x 109/l and a haemoglobin level of 9 g/dl (after transfusion if necessary). H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O Διαβάστε το πλήρες έγγραφο